IRD Opus Genetics, Inc.: Net earnings per share for the last four quarters

Official company branding of Opus Bio (IRD)

The Opus Genetics Inc (IRD) price chart illustrates EPS dynamics, which currently stand at 10.80. The business faces threats due to a small patient population and difficulties with insurance company reimbursements. Strict safety regulations and drug delivery patents create a high barrier to entry. Development relies on university licenses, as acquiring other firms is impossible due to a lack of funds.

Opus Genetics Inc (IRD): Earnings per share for the last twelve months from 11/23/2025 to 11/14/2026

IRD (Opus Bio): analytical breakdowns and indicator data

- price and consensus price forecast:
Market Price Opus Genetics Inc|IRD - Price Target Chart
- company stock capitalization data:
Market Capitalization Opus Genetics, Inc.|IRD - Total Company Value
- book value of equity indicators:
Net Asset Value per Share Opus Genetics|IRD - Company Book Value|Market Capitalization to Net Assets opusgtx.com|IRD - Cumulative Company Assets
- debt and liquidity data:
Total Debt to Capital Opus Genetics Inc|IRD - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Opus Genetics Inc|IRD - Company Total Debt|Debt to Net Assets Ratio Opus Genetics, Inc.|IRD - Company Long-Term Debts|Short-Term Indebtedness Opus Genetics|Immediate Liquidity opusgtx.com
- net income and valuation ratios data:
IRD - Company Net Income|Net Profit Forecast Opus Genetics Inc|IRD - P/E Multiple|Projected Price to Earnings Ratio Opus Genetics Inc|IRD - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Opus Genetics, Inc.|IRD - Operating profit EBITDA|Net earnings per share for the last four quarters Opus Genetics|IRD - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months opusgtx.com|IRD - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year Opus Genetics Inc
- revenue and sales details:
IRD - Company Sales|Company Future Revenue Opus Genetics Inc|IRD - P/S Multiple|Market Cap to Expected Sales Ratio Opus Genetics, Inc.
Fundamental valuation:Opus Genetics IRD
Mass-produced product of Opus Genetics

Opus Genetics Inc (IRD) is monopolizing the gene therapy niche for vision restoration by creating a unique product with no market alternatives. Analyzing the historical YoY ttm net income per share growth rate allows for a comparison of EPS dynamics with 10-K and 10-Q report data, revealing hidden changes in the cost of capital and the revaluation of cash flows to determine the asset's real margin of safety.

Competitor analysis for Opus Genetics Inc

Net earnings per one share for the last twelve months alcon.com|Bausch + Lomb (BLCO) - Earnings per share for the last twelve months|GKOS - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Apellis Pharmaceuticals Inc|Net earnings per one share for the last twelve months belitebio.com BLTE|Earnings per share for the last twelve months Ocular Therapeutix (OCUL)|HROW: Earnings per one share for the last 12 months|Viridian Therapeutics, Inc. - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) LENZ Therapeutics Inc LENZ|OCS - Earnings per share for the last twelve months|Net earnings per share for the last four quarters EyePoint Corp EYPT|KOD (Kodiak Sciences Inc.) - Net earnings per share for the last 12 months|Aldeyra Therapeutics, Inc. - Earnings per share for the trailing year|KALA (KALA BIO Inc.) - Net earnings per share (EPS TTM)|OKYO - Net earnings per share for the trailing year|Net earnings per share (EPS TTM) ADVM|OTLK - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Clearside Biomedical CLSD|NBY: Earnings per share for the last 12 months|Kiora Pharma - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Alimera Sciences|EYEN (eyenovia.com) - Net earnings per share for the last 12 months|GHSI: Earnings per share for the last four quarters|OCUP (Ocuphire Pharma, Inc.) - Net earnings per share (EPS TTM)|opthea.com (OPT) - Net earnings per share for the last four quarters